Independent information services
Cedar Threshold offers guides, comparisons, research summaries, and decision frameworks for people trying to understand whether ibogaine is legal in the United States.
What we make available
Our information is organized around legal status, regulatory pathways, research context, and safety considerations. It is designed to help readers place a short answer in context rather than treat it as medical or legal advice.
We map the distinction between a substance’s federal status, research activity, and questions people may encounter when seeking information about access. For a focused starting point, our ibogaine legality guide keeps the central question visible without reducing it to a slogan.
Our frameworks distinguish law, policy, clinical research, and practical claims so readers can identify which question they are actually trying to answer. The U.S. ibogaine legal-status overview provides the broader context those distinctions require.
When people compare information about care outside the United States, we explain why cost claims, legal setting, and safety questions should not be collapsed into one choice. Our Mexico cost context is intended as an informational comparison, not a treatment recommendation.
We summarize the difference between investigational research and ordinary availability. The U.S. Food and Drug Administration explains that an Investigational New Drug application is a pathway for clinical investigation, not an approval for general marketing.
Method
Cedar Threshold is built for clear, careful context in a fast-changing area. Our approach and sourcing principles explain why we separate what is established from what needs further verification.
Ibogaine is commonly described as a psychoactive substance derived from the iboga plant; background descriptions can be checked against the ibogaine reference overview. That background does not determine legal status, safety for any individual, or whether a particular claim is reliable.
We keep safety considerations present when discussing law and access. The National Institute on Drug Abuse notes that research is used to improve understanding of drugs and their effects, a reason to treat claims about substance use with appropriate caution and context.
Information can clarify a question. It cannot replace medical judgment, legal counsel, or individualized care.
Reference tools
These resources are structured for comparison and orientation, with an emphasis on source transparency and the limits of general information.
FAQ-style explanations address the terms people often encounter while looking into legality, research, and access. For U.S.-specific framing, visit the ibogaine in the United States resource.
Comparisons are most useful when they retain their limits: a directory does not establish oversight, safety, or suitability. The clinic-information comparison resource is presented for context, not as an endorsement or referral.
Terms such as “controlled substance,” “investigational,” and “approved” carry different implications. The DEA controlled-substances schedules offer an official reference point for understanding why federal classification is relevant to legal discussions.
A measured starting point
Cedar Threshold is an independent resource on ibogaine law, policy, and safety. Use its guides to orient your questions, and seek qualified medical or legal guidance for decisions that require it.
Explore the legal overview